Informações

Modo de Usar

Consumir 1 comprimido (210mg de cafeína) ou até 2 comprimidos (420mg de cafeína) ao dia ou conforme recomendado por nutricionista ou médico). Evite o consumo à noite ou com estômago vazio.

Consumir 1 frasco 60 ml (210mg de cafeína) ou até 2 frascos (420mg de cafeína) ao dia ou conforme recomendado por nutricionista ou médico). Evite o consumo à noite ou com estômago vazio.

Recomendações

ESTE PRODUTO FORNECE 210MG DE CAFEÍNA POR PORÇÃO. ESTE PRODUTO NÃO SUBSTITUI UMA ALIMENTAÇÃO EQUILIBRADA E SEU CONSUMO DEVE SER ORIENTADO POR UM NUTRICIONISTA OU MÉDICO. ESTE PRODUTO NÃO DEVE SER CONSUMIDO POR CRIANÇAS, GESTANTES, IDOSOS OU PORTADORES DE ENFERMIDADES. NÃO É RECOMENDADO O CONSUMO COM BEBIDA ALCOÓLICA.


Dúvidas Frequentes - FAQ

  1. Qual a idade mínima que é preciso ter para tomar Vivamil? O que acontece se um adolescente tomar o produto?

  2. Quais são os efeitos de Vivamil? Ele vicia?

  3. Vivamil poderia ser comparado ao café?

  4. É seguro tomar Vivamil? Quais são os efeitos colaterais?

  5. Depois de consumir Vivamil, em quanto tempo aparecem os efeitos?

  6. Como Vivamil age no meu corpo?

  7. Se eu estiver muito cansado e precisar de uma animada rápida, posso tomar 2 ou 3 comprimidos ao mesmo tempo?

  8. Se eu tiver dificuldade para engolir, posso mastigar o comprimido de Vivamil?

  9. Posso usar o Vivamil para substituir o sono?

  10. Existe alguma informação sobre o uso prolongado de Vivamil?

  11. Diabéticos podem consumir Vivamil?

  12. Posso usar o Vivamil se eu estiver grávida ou amamentando?

A monografia para produtos estimulantes pode ser conferida no Federal Register, Volume 40, Número 236, segunda-feira, 8 dezembro, 1975, páginas 57292-57329 (Súmula n º 75 NO244).

Caso seja do seu interesse, solicite uma cópia por escrito para:

FDA/Dockets Management Branch
5600 Fishers Lane
Rockville, MD 20852

  • Lieberman HR. The effects of ginseng, ephedrine, and caffeine on cognitive performance, mood, and energy. Nutrition Reviews 2001; 59(4): 91-102.
  • Caffeine Monograph. FDA Federal Register. CFR 21, Part 338, 339, 340. December 1975; 40(236): 57292-57329.
  • Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Addit Contam 2003; 20(1): 1-30.
  • Smith A. Effects of caffeine on human behavior. Food and Chemical Toxicology 2002; 40: 1243-1255.
  • Berardi RB, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ. Handbook of Nonprescription Drugs. 13th Edition; 2002. 986.
  • Windholz M, Budavari S, Blumetti RF, Otterbein ES. The Merck Index. Tenth Edition; 1983: 1606.
  • Lieberman HR. The effects of ginseng, ephedrine, and caffeine on cognitive performance, mood, and energy. Nutrition Reviews 2001; 59(4): 91-102.
  • Warburton DM and Bersellini E. An evaluation of a caffeinated taurine drink on mood, memory, and information processing in healthy volunteers without caffeine abstinence. Psychopharmacology 2001; 158: 322-28.
  • Frewer LJ and Lader M. The effects of caffeine on two computerized tests of attention and vigilance. Human Psychopharmacology 1991; 6: 119-128.
  • Ruijter J, Ruiter MB, Snel J, Lorist MM. The influence of caffeine on spatial selective attention: an event-related potential study. Clinical Neurophysiology 2000; 111: 2223-2233.
  • Lorist MM, Snel J, Kok A, Mulder G. Acute effects of caffeine on selective attention and visual search processes. Psychophysiology 1996; 33: 354-361.
  • Stephenson PE. Physiologic and psychotropic effects of caffeine on man. Journal of the American Dietetic Association 1977; 71: 240-247.
  • Mitchell VE, Ross S, Hurst PM. Drugs and placebos: effects of caffeine on cognitive performance. Psychol. Rep 1974; 35: 875.
  • Lorist MM, Snel J, Kok A. Influence of caffeine on information processing stages in well-rested and fatigued subjects. Psychopharmacology 1994; 113: 411-421
  • Koelega HS. Stimulant drugs and vigilance performance: a review. Psychopharmacology 1993; 111: 1-16.
  • Knight DC. Secrets of time management. Office Solutions. April 2002; 4(19):18.
  • Schor J. Why americans should rest. New York Times. September 2002, Section A, Column 2, pg 15.FDA panel assessment, Federal Register. CFR 21, Parts 338, 339, 340. – December 1975; 40(236): 57325-6.
  • Eckman, Bruce, Ph.D., “Consumers Perceptions and Evaluation of New Forms within the caffeine pill category: broadening the Vivarin® Appeal,” Creative Insights, Inc., September 2001.
  • FDA Federal Register for Caffeine – July 1988.
  • Caffeine. American Hospital Formulary Service (AHFS) 2002: 2361.
  • Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki kH, Blanchette PL, Curb JD, Popper JS, White LR. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000; 283(20): 2674-9.
  • Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 2001; 50(1): 56-63.
  • Maia L, Mendonca A. Does caffeine intake protect from Alzheimer’s disease? European Journal of Neurology 2002; 9: 377-382.
  • Lietzmann MF, Stampfer MJ, Spiegelman D, Colditz GA, Giovannucci EL. Coffee intake is associated with lower risk of symptomatic gallstone disease in women. Gastroenterology 2002; 123(6): 1823-30.
  • Leitzmann MF, Stampfer MJ, Willett WC, Spiegelman D, Colditz GA, Giovannuci EL. Coffee intake is associated with lower risk of symptomatic gallstone disease in men. JAMA 1999; 281(22): 2106-2111.
  • Smith A. Effects of caffeine on human behavior. Food and Chemical Toxicology 2002; 40: 1243-1255.
  • Gilman AG. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 2001; Tenth Edition. New York. 636.
  • Dews PB, Curtis GL, Hanford KJ, and O’Brien CP. The frequency of caffeine withdrawal in a population-based survey and in a controlled, blinded pilot experiment. J Clin Pharmacol 1999; 39: 1221-1232.
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 1994; Fourth Edition. Washington D.C.
  • Daly JW, Holmen J, Fredholm BB. Is caffeine addictive? The most widely used psychoactive substance in th world. Lakartidningen 1998; 95(51-52): 5878-83.
  • Food Labeling; Requirements for Nutrient Content Claims, Health Claims and Statements of Nutritional Support for Dietary Supplements; Federal Register/Vol 62, No 184, Sept. 23, 1997, pg 49,859 – 49,868.
  • Dawber TR, Kannel WB, Gordon T. Coffee and cardiovascular disease. Observations from the Framingham Study. New England Journal of Medicine 1974; 291(17): 871-874.
  • Wilson PW, Garrison RJ, Kannel WB, McGee DL, Castelli WP. Is coffee consumption a contributor to cardiovascular disease? Arch Intern Med 1989; 149: 1169-1172.
  • Grobbee DE, Rimm EB, Giovannucci E, Colditz G, Stampfer M, Willett W. Coffee, caffeine, and cardiovascular disease in men. New England Journal of Medicine 1990; 323(15): 1026-1032.
  • Nehlig A, Debry G. Coffee and cancer: a review of human and animal data. World Rev Nutr Diet 1996; 79: 185-221.
  • Nehlig A, Debry G. Effects of coffee and caffeine on fertility, reproduction, lactation, and development. Review of human and animal data. J Gynecol Obstet Biol Reprod 1994; 23(3): 241-56.
  • Michaud DS, Giovannucci E, Willett W, Colditz GA, Fuchs CS. Coffee and alcohol consumption and the risk of pancreatic cancer in two prospective U.S. cohorts. Cancer Epidemiology, Biomarkers, and Prevention 2001; 10: 429-437.
  • Pozniak PC. The carcinogenicity of caffeine and coffee: a review. J Am Diet Assoc 1985; 85(9): 1127-33.Rosenberg L. Coffee and tea consumption in relation to the risk of large bowel cancer: a review of epidemiologic studies. Cancer Letters 1990; 52: 163-171.
  • Ron E, Lubin B. Consumption of methylxanthine containing beverages and the risk of breast cancer. Cancer Letters 1990; 53: 81-90.
  • Heaney RP. Effects of caffeine on bone and the calcium economy. Food Chem Toxicol 2002; 40(9): 1263-70.
  • Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, Kiel DP. Risk factors for longitudinal bone loss in elderly men and women: The Framingham Osteoporosis Study. J Bone Miner Res 2000; 15(4): 710-20.
  • Grainge MJ, Coupland CA, Cliffe SJ, Chilvers CE, Hosking DJ. Cigarette smoking, alcohol and caffeine consumption, and bone mineral density in postmenopausal women. The Nottingham EPIC Study Group. Osteoporos Int 1998; 8(4): 355-63.
  • Lloyd T, Rollings N, Eggli DF, Kieselhorst K, Chinchilli VM. Dietary caffeine intake and bone status of postmenopausal women. Am J Clin Nutr 1997; 65(6): 1826-30.
  • National Institute of Health. Center for Evaluation of Risks to Human Reproduction (CERHR): Caffeine. October 2002. http://cerhr.niehs.nih.gov/genpub/topics/caffeine-ccae.html
  • Christian MS, Brent RL. Teratogen update: evaluation of the reproductive and developmental risks of caffeine. Teratology 2001; 64(1): 51-78.
  • Barbieri RL. The initial fertility consultation: recommendations concerning cigarette smoking, body mass index, and alcohol and caffeine consumption. Am J Obstet Gynecol 2001; 185(5): 1168-73.
  • Warburton DM and Bersellini E. An evaluation of a caffeinated taurine drink on mood, memory, and information processing in healthy volunteers without caffeine abstinence. Psychopharmacology 2001; 158: 322-28.
  • Maia L, Mendonca A. Does caffeine intake protect from Alzheimer’s disease? European Journal of Neurology 2002; 9: 377-382.
  • Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki kH, Blanchette PL, Curb JD, Popper JS, White LR. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000; 283(20): 2674-9.
  • Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 2001; 50(1): 56-63.
  • FDA panel assessment, Federal Register. CFR 21, Parts 338, 339, 340. December 1975; 40(236): 57325-6.
  • Eckman, Bruce, Ph.D., “Consumers Perceptions and Evaluation of New Forms within the caffeine pill category: broadening the Vivarin® Appeal,” Creative Insights, Inc., September 2001.

Assine nossa
Newsletter